7.29
-0.11(-1.49%)
Currency In USD
| Previous Close | 7.4 |
| Open | 7.41 |
| Day High | 7.54 |
| Day Low | 7.11 |
| 52-Week High | 14.44 |
| 52-Week Low | 7.11 |
| Volume | 1.59M |
| Average Volume | 1.16M |
| Market Cap | 626.17M |
| PE | -12.79 |
| EPS | -0.57 |
| Moving Average 50 Days | 8.86 |
| Moving Average 200 Days | 9.17 |
| Change | -0.11 |
If you invested $1000 in Anavex Life Sciences Corp. (AVXL) 10 years ago, it would be worth $1,340.07 as of November 10, 2025 at a share price of $7.29. Whereas If you bought $1000 worth of Anavex Life Sciences Corp. (AVXL) shares 5 years ago, it would be worth $1,345.02 as of November 10, 2025 at a share price of $7.29.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Control Group
GlobeNewswire Inc.
Oct 29, 2025 11:30 AM GMT
ADAS-Cog13 difference −12.78 (P < 0.0001) with oral blarcamesine treatment compared to ADNI control group at Week 144 77.4 Weeks (17.8 Months) ‘time saved’ with oral blarcamesine compared to ADNI Restoring impaired Autophagy − preceding amyloid-beta
Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference ‘Connecting Science and Communities: The Future of Dementia Care’
GlobeNewswire Inc.
Oct 10, 2025 11:30 AM GMT
Presentation title: “Advancing Alzheimer’s Disease Care: Convenience for Both Patients and Families with Oral Blarcamesine” NEW YORK, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinic
Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 Program
GlobeNewswire Inc.
Oct 02, 2025 11:35 AM GMT
ANAVEX3-71-002 trial achieved its primary endpoint demonstrating safety and tolerability in both male and female adults Oral ANAVEX®3-71 tablet exhibits superior pharmacokinetics compared to the current immediate-release oral capsule, enabling once-d